Background. The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression. Estimated glomerular filtration rate (eGFR), now widely used to monitor chronic kidney disease (CKD) progression, was not previously examined in IDNT. This post hoc analysis aimed to confirm IDNT results using eGFR as principal outcome measure. Methods. Mean change in eGFR from baseline (neGFR) was analysed using linear mixed-effects models over time and analysis of covariance at end of study on an intentionto-treat basis. Potential treatment response moderators and/ or mediators assessed were CKD stage, blood pressure (BP) and proteinuria. Results. Irbesartan significantly slowed the rate of DeGFR decline from 6 to 21 months (P ¼ 0.0048) and 24 to 48 months (P < 0.0001) versus amlodipine and placebo, despite a faster decline in the first month. The longer patients remained on irbesartan the greater the benefit (model-derived estimates for 6-21 and 24-48 month periods were À0.3354 and À0.1947 mL/min/1.73m 2 /month, respectively). Irbesartan slowed the rate of DeGFR decline irrespective of baseline CKD stage, BP or proteinuria level. Irbesartan produced rapid and sustained proteinuria reductions, which only partially mediated treatment response. Irbesartan increased serum potassium, but levels stabilized from 6 to 48 months. Conclusions. In patients with established Type 2 diabetic nephropathy and CKD Stages 1-5, irbesartan safely and significantly slowed the rate of DeGFR decline (À2.34 mL/min/ 1.73m 2 /year) compared to amlodipine (À3.76 mL/min/ 1.73m 2 /year) and placebo (À3.52 mL/min/1.73m 2 /year). This rate of decline was slower with longer duration of irbesartan treatment and only partly explained by observed reductions in BP and proteinuria.
Introduction
In 2010, the estimated prevalence of diabetes mellitus in adults was 285 million worldwide and is expected to rise to 439 million by 2030 [1, 2] . Diabetes, followed by hypertension, is the leading cause of end-stage renal disease (ESRD) in Europe [3] and the USA [4] and is associated with high cardiovascular morbidity and mortality [4] .
In Europe, diabetes-related ESRD incidence increased by 6% annually during the period 1997-2000 and 2.4% from 2000 to 2006 [5] . In the USA, incidence increased from 1990 to 1996, but in 1996-2006, it decreased by 3.9% annually [6] . The reasons are uncertain but may include earlier detection and treatment of kidney disease and improved management of ESRD risk factors, particularly glycaemia and hypertension [6] , to recommended targets [7, 8] . Use of renin-angiotensin-aldosterone system (RAAS) inhibitors in patients with Type 2 diabetes mellitus and microalbuminuria is renoprotective [9] and~77% of chronic kidney disease (CKD) patients with diabetes in the USA receive such agents [4] . However, physicians are hesitant to administer RAAS inhibitors to patients with CKD, particularly at later stages, because of concerns about acute worsening of renal function and/or hyperkalaemia [10, 11] . Indeed, US data show that the current use of such agents decreases as patients progress towards ESRD [4] .
Recent clinical trials have shown that the angiotensin II receptor blockers (ARBs) irbesartan [12] and losartan [13] slow the progression of established diabetic nephropathy. The Phase III Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed progression of established Type 2 diabetic nephropathy compared to placebo and amlodipine [12] .
Since the primary IDNT results were published, guidelines now recommend that estimated glomerular filtration rate (eGFR) is used as a preferred measure of renal function changes [7, 8, 14, 15] . CKD has been categorized into five stages based upon eGFR [8] .
IDNT did not report eGFR. Therefore, the objectives of this study were (i) to perform post hoc analyses of IDNT data using eGFR to assess progression of nephropathy in Type 2 diabetes, hypothesizing that the rate of eGFR decline will differ between the three treatment groups and (ii) to determine whether results of IDNT were confirmed when using eGFR as the principal outcome measure.
Materials and methods

IDNT design
This has been described previously [12, 16, 17] . Patient inclusion criteria were age 30-70 years, hypertension [>135 mmHg seated systolic blood pressure (SBP), >85 mmHg seated diastolic blood pressure (DBP) or documented anti-hypertensive treatment], plus Type 2 diabetes with nephropathy (proteinuria !900 mg/24 h and serum creatinine 1.0-3.0 mg/dL for women and 1.2-3.0 mg/dL for men). Any ARBs, angiotensin-converting enzyme inhibitors and calcium channel blockers were stopped for at least 10 days prior to the study screening; during this time, BP was controlled using other agents.
Eligible patients were randomized to receive irbesartan (75-300 mg/ day), amlodipine (2.5-10 mg/day) or placebo. The target BP for all participants was SBP 135 mmHg or 10 mmHg lower than at screening if >145 mmHg, plus DBP 85 mmHg.
The following parameters were measured at baseline and every 3 months: survival, ESRD, serum creatinine and potassium and BP. Serum creatinine, potassium and BP were also measured after 1, 2 and 4 weeks and after 2 months. Twenty-four-hour urinary protein excretion was measured at baseline, 2 and 3 months, and then once every 6 months.
The primary end point was doubling of serum creatinine from baseline, ESRD (initiation of dialysis, renal transplantation or serum creatinine !6.0 mg/dL) or death [12] . Analysis of treatment effects on change in eGFR over time. Mean change in eGFR from baseline (neGFR) with treatment was analysed using linear mixed-effects models employing S-Plus Professional v6.1 Statistical Software (Insightful Corp.). Fixed effects included time and treatment, with random effects for patient and time. Quadratic and cubic polynomial time terms accounted for non-linearity of neGFR over time. The S-Plus spatial correlation function corRatio and variance function varPower most accurately corrected for serial correlation and heteroscedasticity, respectively.
Contrasts with placebo as reference category generated estimates for intercept and slope and their associated P-values for each treatment. Given that change from baseline scores were analysed, with time 0 data containing no variation, statistical models used data from 1 week onwards. Thus, intercept terms gave an indication of immediate treatment effect and slope terms longer term changes over time. However, graphical representations of the data included baseline data. In addition to mixed-effects analyses, analysis of covariance (ANCOVA) using baseline eGFR as covariate and the last observation carried forward (LOCF) method compared treatment differences in DeGFR at end of study (EOS).
To identify potential time points when irbesartan-associated DeGFR diverged from DeGFR observed with placebo or amlodipine, treatmentby-time interaction terms generated multiple slope estimates using placebo and amlodipine groups as a combined reference category. Transitions between statistically insignificant and significant slopes determined relevant points of divergence. Overall rates of change in neGFR for the identified transition periods were then generated from the fitted model predictions.
Moderators and mediators of treatment effects on DeGFR. The influence of baseline CKD stage, blood pressure (BP) parameters, change in BP parameters, baseline proteinuria and change in proteinuria as potential moderators and mediators of treatment response were investigated according to the general statistical principles outlined by Kraemer et al. [18] .
BP and DeGFR. Baseline seated DBP and seated SBP were entered into mixed-effects models with or without baseline BP-by-treatment interaction terms to identify independent and moderating influences on DeGFR treatment response.
Change from baseline DBP (nDBP) or SBP (nSBP) was entered into mixed-effects models as covariates with associated main effect, two-way and three-way interaction terms, while controlling for baseline DBP or SBP, to identify independent and meditating influences on DeGFR treatment response. Centred nDBP or nSBP variables compared interaction terms with reference to individuals with average changes in BP as most patients showed falls in BP.
Best-fitting models were identified by stepwise omission of nonsignificant terms and comparing the model fit parameters Akaike information criterion, Bayesian information criterion and change in log-likelihood ratio [19] .
Proteinuria and DeGFR. The potential influence of baseline proteinuria and treatment-induced changes in proteinuria from baseline (DProt) on neGFR was analysed similarly to the BP moderator/mediator analysis. Although raw proteinuria measurement distribution was positively skewed, DProt was normally distributed. DProt was therefore entered into mixedeffects analyses untransformed, but baseline proteinuria was log transformed prior to analysis. Using uncentred, DProt was considered to be most meaningful as patients showed both increases and decreases from baseline. Because the first non-baseline proteinuria measurement was at 2 months, intercept terms refer to initial treatment effects at 2 months and not at 1 week as for eGFR, BP and potassium analyses.
In the event of full or partial mediation over time, mean differences in neGFR between patients classified by proteinuria increase from baseline versus proteinuria decrease at EOS for each treatment group was analysed using LOCF ANCOVA with baseline eGFR as covariate.
Changes in serum potassium with treatment. Mean change in serum potassium from baseline (nK 1 ) with treatment was examined using mixed-effects models.
Results
Baseline characteristics and patient disposition
The baseline characteristics of the study population have been described in detail elsewhere [12, 17] , but a summary is provided in Table 1 . There were no significant differences in baseline eGFR between treatment groups.
Treatment effects on DeGFR
Irbesartan significantly slowed the rate of decline in DeGFR relative to placebo and amlodipine treatment as demonstrated by positive changes in slope compared with placebo and amlodipine. However, the intercept value suggested that at 1 week, irbesartan initially decreased DeGFR versus placebo ( Figure 1 and Supplementary Table 1) .
Using the LOCF method, ANCOVA confirmed that the effect of treatment was significant (d.f. ¼ 2; F ¼ 7.755; P ¼ 0.0004) and that DeGFR deterioration at EOS was significantly less in patients treated with irbesartan than with placebo or amlodipine (Supplementary Table 1 ).
Analysis of slopes at each time point showed transitions from significant to insignificant values at 3 months and from insignificant to significant values at 21 months. Analysis of slopes at 1 week to 3 months, 6-21 months and 24-48 months confirmed that irbesartan initially increased the rate of DeGFR deterioration compared with placebo and amlodipine but that after 6 months, the rate of DeGFR deterioration was slower in irbesartan-treated patients (Table 2a) . The early decline with irbesartan appeared to be apparent in the first month of treatment only ( Figure 1 ). Fitted model predictions generated overall estimated the rates of DeGFR change for these time periods (Table 2b) , with estimated rates of DeGFR decline from 24 months of 2.34, 3.76 and 3.52 mL/min/1.73m 2 /year for irbesartan, amlodipine and placebo, respectively.
Analysis using the CKD-EPI equation [20] did not materially affect the results (Supplementary Table 2 ).
Moderators and mediators of treatment effect
The rate of decline in DeGFR was greater in those with earlier CKD stages (Figure 2a BP and DeGFR. Baseline BP and DeGFR. Higher baseline SBP increased both initial DeGFR deterioration at 1 week (DeGFR intercept À0.03312, P < 0.0001) and later rate of deterioration between 2 weeks and 48 months (DeGFR slope À0.00175, P ¼ 0.0024). Adding a treatment-by-baseline SBP interaction term to the model had no significant effect, indicating that irbesartan reduced the rate of DeGFR deterioration irrespective of baseline SBP level. Inclusion of baseline DBP had no effect on the results.
Change in BP with treatment. Both nDBP and DSBP showed highly significant initial falls with irbesartan (nDBP and DSBP intercepts À3.30671 and À6.01053, respectively; both, P < 0.0001) and amlodipine (nDBP and DSBP intercepts À3.40545 and À4.55622, respectively; both, P < 0.0001) compared with placebo, as expected. However, subsequent to this initial decline, slopes remained parallel for all treatment groups (Figure 3 ).
Change in DSBP and DeGFR with treatment while controlling for baseline SBP. Given the greater decline in BP parameters with active treatments compared with placebo, the relative improvement in rate of DeGFR deterioration with irbesartan might have been explained by its BP lowering effect. To explore this, a mixed-effects analysis was performed entering baseline BP parameters, centred mean change from baseline BP parameters and treatment into the model as (i) main effects; (ii) the two-way interactions months-by-BP and BP-by-treatment and (iii) a three-way interaction term, months-by-BP-by-treatment (Supplementary Table 3 ).
The nSBP term demonstrated that at 1 week, there was a positive association with nSBP and improved DeGFR (DeGFR intercept 0.07146; P < 0.0001), but the Months: DSBP term showed that this effect became weaker over time (DeGFR slope À0.00115; P < 0.0001) (Supplementary Table  3 ). In addition, a significant interaction was noted between initial DSBP and irbesartan (DeGFR intercept 0.02831; P ¼ 0.0002), suggesting that initial changes in SBP may partially mediate initial improvements in DeGFR with irbesartan (Supplementary Table 3 ). However, the Months:Baseline SBP slope term (À0.00201; P ¼ 0.0008) showed that high baseline SBP continued to drive the rate of DeGFR deterioration, even after these initial treatment effects were taken into account. Finally, even after controlling for baseline SBP and DSBP in this analysis, the Months:Treatment with irbesartan term remained significant (DeGFR slope 0.10499, P ¼ 0.0001), indicating that irbesartan-induced changes in SBP did not mediate the long-term effect of irbesartan on rate of DeGFR change over time. No significant findings were observed for DBP parameters.
Proteinuria and DeGFR. Baseline proteinuria and DeGFR. Higher baseline proteinuria increased both initial DeGFR deterioration at 2 months (DeGFR intercept À1.29541; P < 0.0001) and later rate of deterioration between 3 and 48 months (DeGFR slope À0.16777; P < 0.0001). The addition of treatment-by-baseline proteinuria interaction moderator term was not significant, indicating that irbesartan reduced the rate of DeGFR deterioration irrespective of baseline proteinuria level.
Change in DProt with treatment. A mixed-effects analysis confirmed that irbesartan significantly decreased initial DProt at 2 months compared with placebo (DProt intercept À0.70141 g/24 h; P < 0.0001), whereas amlodipine treatment did not (DProt intercept 0.08136 g/24 h; P ¼ 0.6404) (Figure 4) . From 3 to 48 months, the rate of change in proteinuria did not differ from placebo with either irbesartan (DProt slope À0.00023; P ¼ 0.9758 versus placebo) or amlodipine (DProt slope 0.00689; P ¼ 0.3731). Thus, irbesartan reduced proteinuria at 2 months and this reduction was maintained from 3 to 48 months at a stable rate of~1 g/ 24 h compared with amlodipine or placebo.
Change in DProt and DeGFR with treatment while controlling for baseline proteinuria. We addressed the possibility that the improvement in rate of DeGFR deterioration seen with irbesartan was explained by its proteinuria-lowering effect using the same methods as those for the BP analyses.
The nProt term demonstrated that at 2 months, there was a positive association with nProt and improved DeGFR (DeGFR intercept 0.90516; P < 0.0001), but the Months:DProt term showed that this effect became weaker over time (DeGFR slope À0.04036; P < 0.0001) (Supplementary Table 4 ). In addition, a significant interaction was noted between initial DProt and irbesartan (DeGFR intercept 0.29873; P ¼ 0.0002), suggesting that initial changes in proteinuria may partially mediate improvements in DeGFR with irbesartan. However, high baseline proteinuria continued to drive DeGFR deterioration both initially (DeGFR intercept À0.91389; P < 0.0001) and the rate of deterioration over time (DeGFR slope À0.18805; P < 0.0001), even when accounting for initial treatment effects. After controlling for baseline proteinuria and DProt, the direct effect of irbesartan on reducing the rate of DeGFR deterioration over time was reduced in both magnitude and level of statistical significance (Months:Treatment with irbesartan DeGFR estimate for slope 0.06838; P ¼ 0.0077). This would suggest that irbesartan-induced proteinuria reduction partially mediated the effect of irbesartan on DeGFR, not only initially but also the rate of deterioration over time. When patients were classified into six groups according to treatment-by-proteinuria change from baseline at EOS either above or below the threshold value of zero (Supplementary Table 5 ), the effect of treatment-by-proteinuria change was significant (d.f. ¼ 5; F ¼ 4.73; P ¼ 0.0003). Only decreases in proteinuria with irbesartan improved DeGFR at EOS. Treatment-by-proteinuria change was then classified using the threshold of mean change from baseline at EOS (À0.40 g/24 h), instead of zero change. In the subgroup of patients with decreases in proteinuria below this threshold, irbesartan-treated patients still showed a relative improvement in DeGFR versus those receiving amlodipine [2.74 mL/min/1.73m 2 ; 95% confidence interval (CI) 1.10-5.19] and placebo (3.15 mL/min/1.73m 2 ; 95% CI 0.93-5.04), despite decreases in proteinuria below this threshold in all three treatment groups.
Changes in serum potassium. Although irbesartan significantly increased K 1 over the first 3 months of treatment compared with placebo and amlodipine (nK 1 slope 1 week to 3 months 0.03555; P < 0.0001 versus amlodipine and placebo), change from 6 to 48 months remained stable, with no significant difference from change seen in the placebo group (nK 1 slope 6-48 months 0.00014; P ¼ 0.8977 versus placebo) ( Figure 5 ). In contrast, following the initial decrease in K 1 with amlodipine (nK 1 slope 1 week to 3 months À0.03881; P < 0.0001 versus placebo), from 6 to 48 months, there was an increase in comparison with placebo (nK 1 slope 6-48 months 0.00433; P ¼ 0.0001 versus placebo) ( Figure 5 ).
Discussion
In patients with established Type 2 diabetic nephropathy, the rate of change in DeGFR declined more slowly on irbesartan compared to amlodipine and placebo. The longer patients remained on irbesartan the slower the rate of loss of . This analysis using eGFR provides information on average rates of progression that is not available when end points such as doubling of serum creatinine are used. Therefore, these data should help clinicians plan care for their patients who are approaching ESRD and supports the use of change in eGFR as an end point in future trials in progressive nephropathies.
Using the CKD-EPI equation [20] did not materially affect the analysis (Supplementary Table 2 ). This is perhaps not surprising as this modification of the original MDRD equation performed better for those with an eGFR >60 mL/min/1.73m 2 , whereas patients in the current study had an average baseline eGFR of <50 mL/min/1.73m
2 . The long-term efficacy of irbesartan was independent of changes in BP. However, high baseline SBP was a driver for both initial and subsequent longer term rate of DeGFR deterioration, with the initial effect of irbesartan on DeGFR being partially mediated by reduced SBP (Supplementary Table 3 ). The implication of this finding is that patients should be initiated on irbesartan early in order to control BP and reduce the subsequent rate of decline of eGFR.
Irbesartan produced a rapid and sustained proteinuria reduction, which partially mediated treatment response both initially and over time (Supplementary Table 4 ). Only in irbesartan-treated patients was proteinuria reduction from baseline at EOS associated with less decline in DeGFR (Supplementary Table 5 ). However, when patients with an >0.4 g/24 h proteinuria reduction were compared across treatments, irbesartan still resulted in less decline in DeGFR compared to amlodipine or placebo.
The results of this post hoc analysis indicate that irbesartan slows the rate of deterioration in DeGFR through mechanisms partly related to initial and long-term proteinuria reduction and, to a lesser extent, initial reduction in SBP. These findings are consistent with previous studies which have shown the importance of reducing tubular protein overload [22, 23] , glomerular capillary hypertension [24] and SBP [25, 26] for improved renal outcomes.
However, none of these potential mechanisms completely accounted for the long-term benefit of irbesartan on rate of DeGFR change. Irbesartan has been shown to reduce endothelial dysfunction, oxidative stress and inflammation [27] [28] [29] [30] [31] [32] [33] . In addition, RAAS blockade decreases collagen formation [34, 35] and improves kidney oxygenation [22] . These experimental results, together with RAAS-independent potentially renoprotective effects observed with some ARBs [36, 37] , warrant further investigation in human diabetes.
It is clinically reassuring that, although irbesartan was associated with a greater initial rate of decline in DeGFR compared with amlodipine or placebo, the rate of loss of DeGFR was significantly reduced in the long term, irrespective of baseline CKD stage. Moreover, the beneficial reduction in the rate of loss of DeGFR was greater as the study progressed. A recent publication from the RE-NAAL investigators analysed outcome based upon stratification into tertiles of initial fall in eGFR [38] . They found that those in the highest tertile of initial loss showed improved long-term renal outcome compared to those with an initial rise. We could not confirm this finding in our patients on irbesartan based upon tertiles of initial fall (data not shown), but as a group, they did better over 4 years than those on amlodipine or placebo despite a greater initial loss of GFR. Patients with established Type 2 diabetic nephropathy should thus be started on treatment early and can be maintained safely long term. Serum potassium levels rose initially on irbesartan but stabilized after 6 months in contrast to amlodipine-treated patients who, after an initial decline, showed a steady rise from 3 to 48 months. Therefore, potassium should be monitored at initiation or modification of irbesartan treatment but thereafter no more frequently than for any other antihypertensive agent or any other clinical indication.
This post hoc analysis of the IDNT, using eGFR as the principal outcome measure, confirmed that irbesartan significantly slowed the long-term rate of decline in eGFR compared to non-RAAS-based therapies, resulting in delayed progression towards ESRD by at least 33%. Irbesartan was equally effective irrespective of baseline CKD stage, and its benefit became stronger with longer duration of treatment, being only partly explained by reductions in BP and proteinuria. These analyses strongly support the early use of treatments which block the RAAS in the management of patients with established Type 2 diabetic nephropathy.
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